Healthcare Industry News: Bristol-Myers Squibb
News Release - April 17, 2008
Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate CommunicationsWOODCLIFF LAKE, N.J., April 17 (HSMN NewsFeed) -- Eisai Corporation of North America today announces the immediate appointment of Robert Laverty as Vice President of U.S. Corporate Communications. In this newly created position, Mr. Laverty will be responsible for overseeing and coordinating all of Eisai's corporate communications strategies and activities in the United States.
Mr. Laverty brings to Eisai more than 22 years of global corporate, product, policy and research and development communications experience in the pharmaceutical industry. Most recently, he served as Vice President, Global Communications, Malaria Initiatives for Novartis AG, where he oversaw all global communications supporting the company's malaria initiative in the developing world. In addition, Mr. Laverty has held several other executive titles at Novartis Pharmaceuticals Corp, including Vice President, External Communication and Vice President, Global Pharma Media Relations.
Earlier in his career, Mr. Laverty held a number of progressively responsible positions in corporate policy, corporate affairs, and product public affairs at Bristol-Myers Squibb Company. He holds a Bachelor of Science degree in pharmacy from St. John's University, Jamaica, New York.
"Mr. Laverty is a welcome addition to our company and will be instrumental in strengthening Eisai's visibility and presence in the U.S. as a top-20 pharmaceutical company," said Lonnel Coats, President & COO, Eisai Corporation of North America. "With his more than two decades of senior communications expertise in the global pharmaceutical industry, Mr. Laverty's contributions to our company will be invaluable, as we continue to fulfill our human health care (hhc) mission to satisfy unmet medical needs and increase benefits to patients and their families."
About Eisai Corporation of North America
Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, Inc., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery. For more information about Eisai, please visit www.eisai.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsIndependent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202